Letter by Escobar et al Regarding Article, “On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with interest the article by Fordyce et al1 about the on-treatment outcomes in patients with worsening renal function treated with rivaroxaban compared with those on warfarin from the ROCKET AF trial (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) data. In this substudy, worsening renal function was defined as a decrease of >20% from screening creatinine clearance measurement at any time point during the study. The main conclusion of this paper was that, among patients with on-treatment worsening renal function, rivaroxaban was associated with lower rates of stroke compared …